Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $5.50.
SGMO has been the subject of several recent analyst reports. Jefferies Financial Group cut their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, December 31st. Barclays increased their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Friday, December 13th. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday, January 2nd.
Read Our Latest Research Report on SGMO
Institutional Investors Weigh In On Sangamo Therapeutics
Sangamo Therapeutics Price Performance
SGMO stock opened at $1.35 on Tuesday. The company has a market capitalization of $281.67 million, a P/E ratio of -1.80 and a beta of 1.29. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The firm’s fifty day simple moving average is $2.12 and its 200-day simple moving average is $1.25.
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.07. The business had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter in the previous year, the firm posted ($0.34) EPS. As a group, sell-side analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current year.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
See Also
- Five stocks we like better than Sangamo Therapeutics
- Differences Between Momentum Investing and Long Term Investing
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- How to Plot Fibonacci Price Inflection Levels
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- Best Aerospace Stocks Investing
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.